Status:
ACTIVE_NOT_RECRUITING
Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia
Lead Sponsor:
AbbVie
Conditions:
Cancer - Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18-99 years
Brief Summary
This study will evaluate real-life effectiveness and use in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).
Eligibility Criteria
Inclusion
- Participants with diagnosed Chronic Lymphocytic Leukemia (CLL) and eligible for venetoclax as per label.
- Participants for whom the physician has decided to initiate CLL treatment with venetoclax.
- Participants the physician believes he can personally follow over all the study period.
- Participants who have been informed verbally and in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control.
Exclusion
- \- Participating in a clinical trial with an investigative drug for CLL within 30 days prior to treatment initiation.
Key Trial Info
Start Date :
March 9 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2026
Estimated Enrollment :
269 Patients enrolled
Trial Details
Trial ID
NCT03415035
Start Date
March 9 2018
End Date
June 1 2026
Last Update
July 16 2025
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
CH Cannes - les Broussailles /ID# 201108
Cannes, Alpes-Maritimes, France, 06414
2
CH CARCASSONNE - Antoine Gayraud /ID# 202530
Carcassonne, Aude, France, 11000
3
CHU Clermont-Ferrand /ID# 170736
Clermont, Auvergne-Rhône-Alpes, France, 63100
4
Clinique Pole santé République /ID# 204658
Clermont-Ferrand, Auvergne, France, 63050